Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
D013167 | Spondylitis, Ankylosing NIH | 1.00 |
D025241 | Spondylarthritis NIH | 0.58 |
D015535 | Arthritis, Psoriatic NIH | 0.50 |
Name (Synonyms) | Correlation | |
---|---|---|
D003095 | Collagen Diseases NIH | 0.33 |
D001172 | Arthritis, Rheumatoid NIH | 0.30 |
D012216 | Rheumatic Diseases NIH | 0.30 |
D001168 | Arthritis NIH | 0.26 |
D003141 | Communicable Diseases NIH | 0.07 |
D007239 | Infection NIH | 0.05 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
D018352 | Coronavirus Infections NIH | 0.03 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0001370 | Rheumatoid arthritis HPO | 0.32 |
HP:0001369 | Arthritis HPO | 0.27 |
Navigate: Correlations HPO
There is one clinical trial.
The prevalence of SARS-CoV-2 infection in chronic inflammatory rheumatic diseases has not yet been widely reported, and has been evaluated only in symptomatic patient samples. The proportion of asymptomatic or mildly symptomatic patients is unknown, in patients who share common symptoms with CoV-2-SARS infection. Our objective is to describe the prevalence of seroconversion to CoV-2-SARS by consecutive screening in routine care of patients with chronic inflammatory rheumatism with serological testing
Description: Proportion of patients with inflammatory chronic rheumatic diseases with positive SARS-CoV-2 serodiagnosis
Measure: Proportion of patients with inflammatory chronic rheumatic diseases with positive SARS-CoV-2 serodiagnosis Time: 1 dayDescription: Proportion of patients with a positive CoV-2 SARS serodiagnosis according to current treatments.
Measure: Proportion of patients with a positive CoV-2 SARS serodiagnosis according to current treatments. Time: 1 dayDescription: Proportion of patients with a positive CoV-2 SARS serodiagnosis according to type of chronic inflammatory rheumatic disease
Measure: Proportion of patients with a positive CoV-2 SARS serodiagnosis according to type of chronic inflammatory rheumatic disease Time: 1 dayDescription: Proportion of patients with a positive CoV-2 SARS serodiagnosis according to demographic characteristics
Measure: Proportion of patients with a positive CoV-2 SARS serodiagnosis according to demographic characteristics Time: 1 dayAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports